Imunon (NASDAQ:IMNN) Stock Rating Upgraded by EF Hutton Acquisition Co. I

Imunon (NASDAQ:IMNN) was upgraded by EF Hutton Acquisition Co. I to a “strong-buy” rating in a report issued on Monday, Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Imunon in a research note on Thursday, August 15th.

Imunon Price Performance

Shares of IMNN opened at $1.03 on Monday. The stock has a market capitalization of $61.85 million, a P/E ratio of -0.51 and a beta of 2.13. Imunon has a twelve month low of $0.48 and a twelve month high of $3.65. The firm has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $1.26.

Imunon (NASDAQ:IMNN) last posted its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04. Sell-side analysts expect that Imunon will post -1.71 EPS for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.